Imaging Biometrics

Elm Grove, WI, United States (for Imaging Biometrics, LLC, the subsidiary) and Saint Helier, Jersey, United Kingdom (for the parent company, Imaging Biometrics Ltd.)  All United Kingdom companies → — Founded 2007 (for Imaging Biometrics, LLC)
Imaging AI Specialist Specialty-Focused AI
Neurosurgery Oncology Radiology
Neurology AI Oncology AI Radiology & Imaging AI
Acquired/Merged (Operating Subsidiary)
Website Claim this company

Products

IB NEURO
Imaging Biometrics
Neurology AI
IB Neuro by Imaging Biometrics is an FDA-cleared AI-powered MRI and CT perfusion platform that generates quantitative relative cerebral blood volume (rCBV) maps, providing critical insights for brain tumor diagnosis, grading, and treatment monitoring.
Contact for pricing

See all 1 product →

About Imaging Biometrics

Imaging Biometrics (IB) is a healthcare AI company that specializes in developing software applications for advanced imaging analysis, primarily focusing on neuro-oncology. Founded in 2007, IB aims to integrate sophisticated imaging analysis into clinical practice to enhance diagnostic precision and workflow efficiency. Their flagship product, IB Neuro™, automates and standardizes MR perfusion imaging to create reliable vascularity maps, which is crucial for assessing brain tumors. The company’s product line has expanded to include IB Diffusion™, IB Delta Suite™, IB DCE™, and IB Rad Tech™, all designed to provide quantitative insights from MRI and CT data for more informed image interpretation and treatment assessment.

For physicians, Imaging Biometrics’ solutions offer scientifically validated and uniquely informative tools for the assessment of brain tumors and other neurological disorders. Their software helps differentiate tumor types, assess residual enhancing tumor after surgery, and evaluate subtle enhancement in complex cases. The platforms provide key physiological information such as true regions of contrast enhancement (void of post-surgical blood products), tumor blood volume, and flow. This quantitative data aids radiologists, surgeons, and oncologists in making better decisions for their patients, both in diagnosis and monitoring treatment response. IB also develops and is sponsoring clinical trials for novel treatments like oral gallium maltolate for rare pediatric brain cancers.

What Physicians Need to Know

Specialization
Imaging Biometrics specializes in advanced neuroimaging solutions, particularly quantitative MRI analysis for brain tumors and other neurological disorders. Their focus is on translating novel imaging technologies into routine clinical workflows.
Key Products
Their core products include IB Neuro™ for standardized MR DSC perfusion images of relative cerebral blood volume, IB Delta T1 maps for delineating contrast-enhancing regions, Fractional Tumor Burden (FTB) Express for automated visualization of tumor vs. non-tumor tissue, and QSMetric for quantitative susceptibility mapping. They also offer IB Diffusion for analyzing diffusion-weighted images and IB DCE for dynamic contrast-enhanced MRI analysis.
Key Differentiators
A key differentiator is their quantitative imaging approach, which provides consistent and accurate output regardless of scanner vendor, field strength, patient, or time point. This allows for direct volumetric comparison over time to monitor treatment response. Their software automates complex imaging tasks, reducing manual steps and errors, and making sophisticated image analysis accessible beyond large research hospitals.
Technology Stack
While specific programming languages or frameworks are not explicitly detailed, Imaging Biometrics' solutions are software applications that accept MRI data as input and automatically compute quantitative and proprietary images as output. They leverage advanced algorithms for image processing and analysis.
Clinical Applications
Their tools are used for diagnosing, planning, and monitoring treatment response for brain tumor patients, assessing neurodegenerative diseases, targeting for deep brain stimulation surgery, and evaluating stroke and ischemia.
Physician Tip

For physicians, Imaging Biometrics' tools offer objective, quantitative data to enhance diagnostic confidence and guide treatment decisions, particularly in neuro-oncology. The automated workflows and standardized outputs can streamline image analysis, reduce variability, and provide critical insights into tumor vascularity, treatment effects, and tissue pathology. The ability to distinguish between true tumor regrowth and treatment effects is a significant advantage.

Imaging Biometrics has a significant global distribution agreement with GE HealthCare, making their products available on GEHC's MR Smart Subscription. This streamlines clinical adoption for hospitals and imaging centers with GEHC MRI scanners. They also have agreements with other platforms like Blackford and MedImageMetric.

Products by Imaging Biometrics

1 product in the directory

IB NEURO
Imaging Biometrics
Neurology AI
IB Neuro by Imaging Biometrics is an FDA-cleared AI-powered MRI and CT perfusion platform that generates quantitative relative cerebral blood volume (rCBV) maps, providing critical insights for brain tumor diagnosis, grading, and treatment monitoring.
Contact for pricing

What the Web Says

Imaging Biometrics (IB) specializes in advanced, quantitatively driven imaging solutions, particularly for brain tumor assessment and neuro-oncology. Their flagship product, IB Neuro, and related tools like Delta T1 and rCBV mapping, are highly regarded by medical professionals for their accuracy, standardization, and ability to differentiate tumor progression from treatment effects. The company has recently undergone a strategic review to focus on its core clinical products, aiming for profitability and improved shareholder value.

Overall: Mixed

Strengths

  • Advanced, quantitatively driven imaging solutions for brain tumors.
  • Scientifically validated and uniquely informative products.
  • High accuracy in identifying active tumors versus treatment effects.
  • User-friendly software and plugins.
  • Standardized processing pipeline for consistent results across platforms.
  • Instrumental in patient management and guiding therapeutic/surgical decisions.

Limitations

  • Previously pursued too many projects without sufficient resources.
  • Shareholder frustration and disappointment in recent years.
  • Costs of phase II trials for gallium maltolate (GaM) were beyond independent means.
  • Limited information available on employer reviews from specified sources.
  • No specific product reviews found on G2, Glassdoor, Capterra, or Reddit directly for Imaging Biometrics' core products (IB Neuro, etc.).
  • General biometric company reviews on Glassdoor and Indeed show mixed to negative sentiment regarding management, pay, and work-life balance, though these are not directly for Imaging Biometrics.

Based on reviews from: Imaging Biometrics: Home, AJR Review Endorses Advanced Imaging Techniques, Validating Imaging Biometrics' Tools for Brain Tumor Assessment | Applied Radiology, Imaging Biometrics touts IB-Neuro recognition - AuntMinnie, Imaging Biometrics to focus on core products after review | The Market Reporter, Imaging Biometrics touts study on DSC-FTB mapping | AuntMinnie, Imaging Biometrics 2026 Company Profile: Valuation, Investors, Acquisition | PitchBook, Biometric Vision Products | Read 12 Reviews on G2, Working at BioMetric Impressions Corp: 4 Reviews - Indeed, BioMetrics Careers and Employment | Indeed.com, NeuroTechnology Products | Read 8 Reviews on G2, IQ Biometrix Products | Read 3 Reviews on G2, Imaging Biometrics Ltd — news & analysis | The Markets - Proactive Investors, Working at BioMetrics: Employee Reviews | Indeed.com, Analysis Of Perfusion And Diffusion-Based Exams. | Imaging Biometrics, Working at Accurate Biometrics: 9 Reviews - Indeed, Capterra: Find The Right Software, Hire a Work From Home Biometric Fingerprint ... - ZipRecruiter, Biometrics today : r/morningsomewhere - Reddit, Realtime Biometrics Reviews 2026: Details, Pricing, & Features - G2, Jumio Products | Read 38 Reviews on G2, Best Medical Imaging Software 2026 | Capterra, Best Free Medical Imaging Software Solutions 2026 - Capterra, Page 2 - Medical Imaging Software - Prices & Reviews - Capterra Canada 2026, Is this a legit cheap mri or ct scan? : r/backpain - Reddit, FAQs - DataAnnotation, Clinical Research, Pharmaceutical, Medical Device Jobs | ICON Plc Careers, Anyone use an AI tool to analyze MRI (for information/curiosity, not diagnostic purposes)? If so what was it and how was your experience? : r/MultipleSclerosis - Reddit, Early careers at AstraZeneca, MyGate Locks

Last updated: 2026-10-17

Videos

News, demos, and interviews about Imaging Biometrics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Imaging Biometrics →

View all on YouTube

Press & Coverage

London Stock Exchange
Imaging Biometrics Expands Global Distribution Agreement with GE HealthCare to Include FTB Express Maps and QSMetricu2122
Imaging Biometrics has expanded its distribution agreement with GE HealthCare to include FTB Express maps and QSMetric software, enhancing access to advanced neuroimaging solutions for brain tumor diagnosis and monitoring. This builds upon their existing agreement for IB Neuro and Delta T1 maps.
2025-12
Investing.com
Imaging Biometrics reports phase II trial results for brain tumor software
Imaging Biometrics announced positive results from the EAF151 Phase II clinical trial, demonstrating that its IB Neuro software can provide early, objective signals of treatment response for recurrent glioblastoma patients. The technology aims to offer response signals within weeks, potentially aiding in earlier determination of treatment effectiveness.
2026-05
RNS News | IBAI - IMAGING BIOMETRICS LIMITED
Imaging Biometrics Enters Agreement with MedImageMetric to Commercialize QSM Technology
Imaging Biometrics, LLC has partnered with MedImageMetric, LLC to commercialize its patented QSMetricu2122 software, an FDA-cleared quantitative susceptibility mapping (QSM) MRI technology. This collaboration aims to enhance diagnostic capabilities for various diseases by measuring tissue response to magnetic fields.
2025-09
Applied Radiology
AJR Review Endorses Advanced Imaging Techniques, Validating Imaging Biometrics' Tools for Brain Tumor Assessment
Imaging Biometrics welcomed an expert consensus in the American Journal of Roentgenology (AJR) endorsing advanced imaging techniques, specifically dynamic susceptibility contrast MRI (DSC-MRI), for evaluating high-grade gliomas. This validates IB's technology, including IB Neuro and Fractional Tumor Burden (FTB) maps, which distinguish tumor progression from treatment effects.
2025-07
Investing.com
Imaging Biometrics releases next-gen medical imaging platform
Imaging Biometrics, LLC announced the release of a new version of IB Clinic, its comprehensive medical image processing suite. This updated platform integrates multiple imaging technologies into a single automated solution, designed to reduce manual intervention in medical image processing workflows.
2025-11
Simply Wall St
Imaging Biometrics Limited Publishes Phase 1 Clinical Trial Results Of Oral Gallium Maltolate In Recurrent Glioblastoma And Reopens Expanded Access Programme
Imaging Biometrics Limited announced the publication of Phase 1 clinical trial results for oral gallium maltolate (GaM) in recurrent glioblastoma in the peer-reviewed journal Neuro-Oncology Advances. The company also reopened its Expanded Access Programme for GaM.
2026-06
AllMind AI News
Imaging Biometrics draws line under cancer drug plans to focus on imaging growth
Imaging Biometrics has decided to discontinue plans for a Phase II trial of gallium maltolate, shifting its focus and resources to its revenue-generating imaging software business. This strategic pivot aims to prioritize commercial growth and financial stability.
2026-06
Kalkine Media
Imaging Biometrics Limited (IBAI) Finalizes Share Sub-Division, Issuing 246,709,789 Shares at £0.005 Each
Imaging Biometrics Limited has officially completed its share sub-division, resulting in 246,709,789 ordinary shares with a nominal value of £0.005 each. This capital restructuring was formally approved by the Jersey Financial Services Commission.
2026-07

Frequently Asked Questions

Imaging Biometrics specializes in advanced imaging analytics, particularly in neuro-oncology. Their key products often involve quantitative imaging biomarkers and AI-driven analysis to assist in the diagnosis, treatment planning, and monitoring of brain tumors, aiming to provide more objective and precise insights from medical images.
Imaging Biometrics is committed to regulatory compliance, with their products like IB Neuro receiving FDA 510(k) clearance. They adhere to medical device regulations to ensure their AI solutions are safe, effective, and meet the necessary standards for clinical use and data privacy.
While specific pricing models would require direct consultation with Imaging Biometrics, they generally offer flexible options that can accommodate various healthcare settings, from individual practices to large hospital networks. Pricing may be structured based on licensing, per-study fees, or subscription models, depending on the product and integration needs.
Imaging Biometrics provides comprehensive support for its platforms, including technical assistance for integration and ongoing maintenance, as well as clinical training to ensure users can effectively utilize their AI tools. This includes resources to help healthcare professionals interpret results and integrate the technology into their existing workflows.
Imaging Biometrics' solutions are designed for seamless integration with existing PACS and EMR systems to minimize disruption and maximize efficiency within clinical workflows. They often collaborate with leading medical imaging and healthcare technology providers to ensure broad compatibility and streamlined data exchange.
Imaging Biometrics, as a subsidiary of a larger entity like IQ-AI Ltd., demonstrates a commitment to long-term stability and continuous innovation in the field of AI-driven medical imaging. Their vision includes ongoing research and development to enhance existing products and introduce new AI applications, ensuring their solutions remain at the forefront of healthcare technology.
Imaging Biometrics prioritizes data privacy and security, implementing robust measures to protect patient information in compliance with regulations like HIPAA. Their AI platforms are designed to process data securely, often utilizing de-identified data for analysis and adhering to strict protocols for data handling and storage.

Related Companies

A2
A2z Radiology Ai
Boston, MA, USA

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]
Pe
Perimeter Medical Imaging AI
Toronto, Canada and Dallas, Texas, USA

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]
SOPHiA GENETICS
Rolle, Switzerland and Boston, Massachusetts, United States

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]
NTL Healthcare
Seongnam-si, Gyeonggi-do, Republic of Korea

NTL Healthcare is a South Korean AI-powered women’s health company specializing in cervical cancer screening and diagnostics. The company has a history dating back to 1996 when it first introduced an analog cervical cancer reading system, Cervicography, to Korea. Since then, NTL Healthcare has evolved its technology, developing the world’s first remote uterine cervical cancer […]
Lumonus
Sydney, Australia

Lumonus is a healthcare technology company that specializes in AI-powered solutions for cancer care, particularly in radiation oncology. The company’s core offering is the Lumonus AI platform, a digital oncology system with AI-native clinical infrastructure designed to automate and orchestrate critical oncology workflows. This platform aims to enhance the quality and speed of care delivery […]
Koios Care
Antwerp, Belgium

Koios Care is a neurology-focused digital medicine company based in Antwerp, Belgium, specializing in AI-powered platforms. The company aims to revolutionize the management of neurological and chronic conditions, with an initial focus on Parkinson’s Disease. Koios Care’s platform utilizes everyday devices like smartphones and smartwatches to passively collect and analyze data, transforming it into objective, […]
Suggest an Edit → | Report an issue
AI Tool Finder
AI-powered search. Results may not be comprehensive.